FASLG and glioma: Accordingly, in patients harboring malignant gliomas, immune function results impaired, getting from these patients an exhibition of varied responses from B cell and T cell signaling defects, identified in an altered transmembrane signaling pathway, such as weakened ability to mobilize calcium (Ca) through Ca-activated potassium channels in glioma patients [19], reduced affinity to IL-2R expression/signaling and apoptosis of T cells through Fas ligand (FasL)-mediated activity.